Revance Therapeutics Company Profile (NASDAQ:RVNC)

About Revance Therapeutics

Revance Therapeutics, Inc. is a biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its TransMTS technology enables delivery of botulinum toxin type A through investigational drug product candidates, including DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical, and DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable. Its botulinum toxin-peptide complex has over two components that contribute to the performance of RT001 and RT002. Its TransMTS peptide provides the delivery across the skin and restricts the toxin molecule to the target site. Then, the botulinum toxin type A provides the mechanism of pharmacologic action and is responsible for the drug effects demonstrated in its clinical trials. Its TransMTS peptide technology serves various purposes depending on whether it is used in a topical formulation or in an injectable formulation.

Industry, Sector and Symbol:

• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Exchange: NASDAQ
• Symbol: RVNC
• CUSIP:

Key Metrics:

• Previous Close: $17.85
• 50 Day Moving Average: $14.90
• 200 Day Moving Average: $16.23
• 52-Week Range: $28,484,000.00 - $12.54
• Trailing P/E Ratio: N/A
• Foreward P/E Ratio: -5.69
• P/E Growth: -0.44
• Market Cap: $499.04M
• Outstanding Shares: 28,484,000
• Beta: 1.35

Profitability:

• Net Margins: -28,586.33%
• Return on Equity: -40.44%
• Return on Assets: -36.60%

Debt:

• Debt-to-Equity Ratio: 0.02%
• Current Ratio: 18.35%
• Quick Ratio: 18.35%

Additional Links:

• Visit Revance Therapeutics' Official Website
• View RVNC on Google Finance
• View RVNC on Yahoo Finance
• View RVNC's Company Profile on Reuters
• Search for Revance Therapeutics Inc. on Google

Companies Related to Revance Therapeutics:

• Luminex Corp. (NASDAQ:LMNX)
• MiMedx Group (NASDAQ:MDXG)
• Genomic Health (NASDAQ:GHDX)
• AveXis (NASDAQ:AVXS)
• Surgery Partners (NASDAQ:SGRY)
• Forward Pharma A/S (NASDAQ:FWP)
• Healthways (NASDAQ:HWAY)
• Aduro Biotech (NASDAQ:ADRO)
• Insmed (NASDAQ:INSM)
• Amphastar Pharmaceuticals (NASDAQ:AMPH)

Earnings

Earnings History for Revance Therapeutics (NASDAQ:RVNC)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call	Details
11/7/2016
8/4/2016	Q216	($0.86)	($0.88)	$0.06 million	$0.80 million	View	N/A
5/9/2016	Q1	($0.83)	($0.71)	$0.08 million		View	Listen
3/2/2016	Q415	($0.86)	($0.83)	$0.09 million	$0.08 million	View	Listen
11/9/2015	Q315	($1.01)	($0.81)	$0.10 million	$0.08 million	View	N/A
8/6/2015	Q415	($0.84)	($0.71)			View	N/A
5/13/2015	Q1	($0.69)	($0.65)			View	Listen
3/2/2015		($0.53)	($0.60)			View	N/A
11/12/2014	Q314	($0.69)	($0.60)			View	N/A
8/12/2014		($0.68)	($0.69)			View	N/A
5/13/2014	Q1 14	($0.87)	($1.93)			View	N/A

(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Revance Therapeutics (NASDAQ:RVNC)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2016	2	($1.07)	($0.66)	($0.87)
Q2 2016	2	($0.91)	($0.91)	($0.91)
Q3 2016	2	($0.95)	($0.93)	($0.94)
Q4 2016	2	($1.02)	($0.95)	($0.99)

(Data provided by Zacks Investment Research)

Dividends

Dividend History for Revance Therapeutics (NASDAQ:RVNC)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Revance Therapeutics (NASDAQ:RVNC)

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Details
6/13/2016	Curtis Ruegg	EVP	Sell	1,000	$18.25	$18,250.00
5/9/2016	Curtis Ruegg	EVP	Sell	1,000	$16.18	$16,180.00
4/11/2016	Curtis Ruegg	EVP	Sell	1,000	$19.11	$19,110.00
3/7/2016	Curtis Ruegg	EVP	Sell	1,000	$20.43	$20,430.00
2/8/2016	Curtis Ruegg	EVP	Sell	1,000	$18.14	$18,140.00
1/6/2016	Curtis Ruegg	EVP	Sell	2,000	$33.06	$66,120.00
11/17/2015	Arthur Peter Bertolino	EVP	Sell	7,753	$39.11	$303,219.83
8/17/2015	Curtis Ruegg	EVP	Sell	3,000	$30.33	$90,990.00
7/17/2015	Curtis Ruegg	EVP	Sell	3,000	$31.03	$93,090.00
6/17/2015	Curtis Ruegg	EVP	Sell	3,000	$33.53	$100,590.00
5/18/2015	Curtis Ruegg	EVP	Sell	3,000	$26.42	$79,260.00
4/17/2015	Curtis Ruegg	EVP	Sell	2,000	$22.23	$44,460.00
3/17/2015	Curtis Ruegg	EVP	Sell	1,500	$18.61	$27,915.00
3/9/2015	Curtis Ruegg	EVP	Sell	500	$18.00	$9,000.00
2/17/2015	Curtis Ruegg	EVP	Sell	1,000	$16.80	$16,800.00
1/20/2015	Curtis Ruegg	EVP	Sell	1,000	$17.25	$17,250.00
12/17/2014	Curtis Ruegg	EVP	Sell	1,000	$16.45	$16,450.00
11/28/2014	L Daniel Browne	CEO	Buy	6,000	$16.67	$100,020.00
11/18/2014	Curtis Ruegg	EVP	Sell	1,000	$16.00	$16,000.00
9/17/2014	Curtis Ruegg	EVP	Sell	2,000	$20.55	$41,100.00
9/17/2014	Jacob Waugh	Insider	Sell	97,713	$20.73	$2,025,590.49

(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Revance Therapeutics (NASDAQ:RVNC)

Date	Headline
	What are Research Firms Saying About Revance Therapeutics, Inc. (NASDAQ:RVNC)? - Frisco Fastball (NASDAQ:RVNC) friscofastball.com - September 24 at 6:25 PM
	Stock Tracker: Earnings & Estimates for Revance Therapeutics, Inc. (NASDAQ:RVNC) - Frisco Fastball (NASDAQ:RVNC) friscofastball.com - September 17 at 6:37 PM
	Revance Therapeutics, Inc. – Value Analysis (NASDAQ:RVNC) : September 14, 2016 (NASDAQ:RVNC) www.capitalcube.com - September 14 at 7:17 PM
	What are Brokerage Firms Saying About Revance Therapeutics, Inc. (NASDAQ:RVNC)? - Frisco Fastball (NASDAQ:RVNC) friscofastball.com - September 14 at 11:31 AM
	Revance Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : RVNC-US : September 13, 2016 (NASDAQ:RVNC) www.capitalcube.com - September 13 at 11:59 AM
	ETF’s with exposure to Revance Therapeutics, Inc. : August 31, 2016 (NASDAQ:RVNC) www.capitalcube.com - August 31 at 12:25 PM
	Revance to Participate in the 2016 Wells Fargo Securities Healthcare Conference (NASDAQ:RVNC) finance.yahoo.com - August 30 at 7:03 PM
	Revance Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : RVNC-US : August 30, 2016 (NASDAQ:RVNC) www.capitalcube.com - August 30 at 10:26 AM
	New Market Report: Revance Therapeutics, Inc. (RVNC) - Financial and Strategic SWOT Analysis Review (NASDAQ:RVNC) www.live-pr.com - August 24 at 6:55 PM
	REVANCE THERAPEUTICS, INC. Financials (NASDAQ:RVNC) finance.yahoo.com - August 16 at 7:21 PM
	ETF’s with exposure to Revance Therapeutics, Inc. : August 15, 2016 (NASDAQ:RVNC) www.capitalcube.com - August 15 at 7:36 PM
	Revance Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : RVNC-US : August 12, 2016 (NASDAQ:RVNC) www.capitalcube.com - August 12 at 10:26 AM
	Revance Therapeutics, Inc. :RVNC-US: Earnings Analysis: Q2, 2016 By the Numbers : August 10, 2016 (NASDAQ:RVNC) www.capitalcube.com - August 10 at 7:43 PM
	Edited Transcript of RVNC earnings conference call or presentation 4-Aug-16 8:30pm GMT (NASDAQ:RVNC) finance.yahoo.com - August 5 at 7:29 PM
	REVANCE THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report (NASDAQ:RVNC) biz.yahoo.com - August 5 at 7:29 PM
	Revance Releases Second Quarter 2016 Results (NASDAQ:RVNC) www.bioportfolio.com - August 5 at 10:14 AM
	New Broker Ratings For Revance Therapeutics Inc (RVNC) - FTSE News (NASDAQ:RVNC) www.ftsenews.co.uk - August 4 at 7:43 PM
	Revance reports 2Q loss (NASDAQ:RVNC) sg.finance.yahoo.com - August 4 at 7:43 PM
	Q2 2016 Revance Therapeutics Inc Earnings Release - After Market Close (NASDAQ:RVNC) biz.yahoo.com - August 4 at 10:26 AM
	Revance Therapeutics Inc (RVNC) Updated Price Targets - FTSE News (NASDAQ:RVNC) www.ftsenews.co.uk - July 25 at 7:22 PM
	Shareholder Alert: Sohmer Law Firm Investigating Revance Therapeutics, Inc. (NASDAQ:RVNC) finance.yahoo.com - July 25 at 10:46 AM
	SHAREHOLDER ALERT: SARRAF GENTILE LLP INVESTIGATING REVANCE THERAPEUTICS, INC. (NASDAQ:RVNC) www.digitaljournal.com - July 22 at 10:11 AM
	Earnings Focus and Crowd Sourced Sentiment Review for Revance Therapeutics, Inc. (NASDAQ:RVNC) - TGP (NASDAQ:RVNC) telanaganapress.com - July 21 at 7:35 PM
	Are Analysts Bullish Revance Therapeutics Inc (NASDAQ:RVNC) After Last Week? - Consumer Eagle (NASDAQ:RVNC) www.consumereagle.com - July 21 at 7:35 PM
	Revance Therapeutics Inc. (RVNC) Drops 6.81% on July 19 - Equities.com (NASDAQ:RVNC) www.equities.com - July 21 at 7:35 PM
	Revance Therapeutics Inc (NASDAQ:RVNC) Stock Technicals at Critical Inflection Point - CML News (NASDAQ:RVNC) news.cmlviz.com - July 21 at 7:35 PM
	Revance Therapeutics to Release Second Quarter 2016 Financial Results Thursday, August 4, 2016 (NASDAQ:RVNC) finance.yahoo.com - July 21 at 4:05 PM
	Is Selling Revance Therapeutics Inc Here a Winning Strategy? - Consumer Eagle (NASDAQ:RVNC) www.consumereagle.com - July 20 at 10:06 AM
	Revance Therapeutics, Inc. (NASDAQ:RVNC): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily (NASDAQ:RVNC) www.engelwooddaily.com - July 20 at 10:06 AM
	Trading Performance and Target Watch for Revance Therapeutics, Inc. (NASDAQ:RVNC) - Press Telegraph (NASDAQ:RVNC) presstelegraph.com - July 18 at 12:48 PM
	These 5 Stocks Are Primed for Breakouts (NASDAQ:RVNC) www.thestreet.com - July 15 at 2:38 PM
	Revance Therapeutics (RVNC) Completes Pre-Phase 3 Meeting with FDA for RT002 Injectable - StreetInsider.com (NASDAQ:RVNC) www.streetinsider.com - July 15 at 12:28 PM
	Crowd Rating and Earnings Recap for Revance Therapeutics, Inc. (NASDAQ:RVNC) - Telanagana Press (NASDAQ:RVNC) telanaganapress.com - July 14 at 7:29 PM
	Eye on Stock Volatility for: Revance Therapeutics, Inc. (NASDAQ:RVNC) - Engelwood Daily (NASDAQ:RVNC) www.engelwooddaily.com - July 14 at 7:29 PM
	4:03 pm Revance Therapeutics announces it is moving forward with an IND submission for phase 3 clinical program for RT002 & other supportive studies required for the BLA filing after its pre-phase meeting with the FDA (NASDAQ:RVNC) finance.yahoo.com - July 14 at 4:03 PM
	Revance Announces Completion of Pre-Phase 3 Meeting with FDA for RT002 Injectable to Treat Glabellar Lines (NASDAQ:RVNC) finance.yahoo.com - July 14 at 4:02 PM
	How Analysts Feel About Revance Therapeutics Inc (NASDAQ:RVNC)? - Press Telegraph (NASDAQ:RVNC) presstelegraph.com - July 13 at 10:06 AM
	Revance Therapeutics Incorporated (NASDAQ:RVNC) Sellers Increased By 11.1% Their Shorts - Engelwood Daily (NASDAQ:RVNC) www.engelwooddaily.com - July 9 at 10:19 AM
	NASDAQ:RVNC Stockholder Notice: Investigation of potential Wrongdoing at Revance Therapeutics Inc (NASDAQ:RVNC) empowerednews.net - July 7 at 10:00 AM
	Stock Moving in on a Recent Low: Revance Therapeutics, Inc. (NASDAQ:RVNC) - Press Telegraph (NASDAQ:RVNC) presstelegraph.com - July 6 at 7:35 PM
	Revance Therapeutics Inc. (RVNC) Drops 5.21% on July 05 - Equities.com (NASDAQ:RVNC) www.equities.com - July 6 at 7:35 PM
	How Analysts Rated Revance Therapeutics Inc (NASDAQ:RVNC) Last Week? - Press Telegraph (NASDAQ:RVNC) presstelegraph.com - July 5 at 6:56 PM
	REVANCE THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Ex (NASDAQ:RVNC) biz.yahoo.com - July 5 at 4:19 PM
	Revance Appoints Industry Leader Julian S. Gangolli to its Board of Directors (NASDAQ:RVNC) finance.yahoo.com - July 5 at 8:00 AM
	Share Performance Recap for: Revance Therapeutics, Inc. (NASDAQ:RVNC) - Press Telegraph (NASDAQ:RVNC) presstelegraph.com - July 4 at 6:23 PM
	Revance Therapeutics Incorporated (NASDAQ:RVNC) Sellers Increased By 11.1% Their Shorts - Press Telegraph (NASDAQ:RVNC) presstelegraph.com - July 2 at 6:47 PM
	Equity Research and Technical Review on Revance Therapeutics, Inc. (NASDAQ:RVNC) - Press Telegraph (NASDAQ:RVNC) presstelegraph.com - June 29 at 9:58 AM
	Revance Therapeutics Inc (RVNC) Broker Price Targets For The Coming Week - Fiscal Standard (NASDAQ:RVNC) www.fiscalstandard.com - June 29 at 9:58 AM
	Revance Therapeutics, Inc. (NasdaqGM:RVNC) Stock Momentum Hits Weakness - CML News (NASDAQ:RVNC) news.cmlviz.com - June 23 at 7:53 PM
	Brokers Issue Average Price Target Of 42.33 On Revance Therapeutics Inc (RVNC) - Fiscal Standard (NASDAQ:RVNC) www.fiscalstandard.com - June 23 at 7:53 PM

Social

Revance Therapeutics (NASDAQ:RVNC) Chart for Monday, September, 26, 2016